Competing risk analysis of primary tracheal carcinoma based on SEER database
Authors Gao HX, He X, Du JF, Yang SH, Wang Y, Zhang JW, Zhao CN
Received 8 October 2018
Accepted for publication 17 December 2018
Published 24 January 2019 Volume 2019:11 Pages 1059—1065
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Beicheng Sun
HongXiang Gao,1 Xuan He,1 JianFei Du,1 SanHu Yang,2 Yang Wang,1 JunWei Zhang,1 ChenNian Zhao1
1Department of Oncology, Chang’An Hospital, Xi’an, Shaanxi, China; 2Department of Thoracic Surgery, Tangdu Hospital, Xi’an, Shaanxi, China
Purpose: To analyze the prognostic factors of primary tracheal carcinoma.
Patients and methods: All patients of primary tracheal carcinoma were extracted from the Surveillance, Epidemiology, and End Results database during 1973–2015. The potential prognostic factors were analyzed by using the competing risk analysis of R statistical software.
Results: A total of 485 eligible patients were enrolled. The univariate analysis indicated that age, sex, diagnostic confirmation, extension, lymph node, metastasis, multiple primary tumors, primary site surgery, and lymph node dissection were statistically significant for the patients’ death due to tracheal tumor. The multivariate analysis indicated that age (P=0.0000, CI: 1.0255–1.0630), lymph node (P=0.0000, CI: 1.6031–3.4890), metastasis (P=0.0100, CI: 1.1342–2.5790), multiple primary tumors (P=0.0000, CI: 0.0276–0.1090), and primary site surgery (P=0.0001, CI: 0.3565–0.7110) were independent prognostic factors affecting survival, and there were significant differences in the stratification of each prognostic factors.
Conclusion: Age, lymph node, metastasis, multiple primary tumors, and primary site surgery were independent prognostic factors of primary tracheal carcinoma.
Keywords: primary tracheal carcinoma, SEER, prognostic factor, competing risk analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]